PCS worked with LumiThera’s scientists and near infrared light (NIR) experts to make the LT-300 a functional reality. The PCS team integrated LumiThera’s optics and light drivers, designing and engineering the platform, housing, patient interface, system electronics and firmware for proof-of-concept prototypes. Our teams then tested and optimized devices for early test and review by LumiThera’s board of medical experts.
The collaboration between LumiThera and PCS achieved the next phase commercialization grant from LSDF and for our part PCS won the Most Innovative Company out of 2200 companies attending the MDM West Conference. Lumithera is now conducting human testing and in the Design for Manufacture (DFM) stage. PCS is proud to be part of the LumiThera team that will be the first to commercialize this impactful, non-invasive light treatment. This life-changing work will address vision loss, prevent blindness and improve the quality of life for people affected by macular degeneration.